After activation, data will be sent to YouTube. Further information here: Data protection
After activation, data will be sent to YouTube. Further information here: Data protection
03.06.2025 - EULAR 2025 Is Just Around the Corner – Here’s What to Expect!
As we count down to the highly anticipated EULAR 2025 Congress, we’re thrilled to share a special preview with none other than Daniel Aletaha, Head of our Division of Rheumatology and current President of EULAR.
In a two-part video interview series, Daniel shares why EULAR 2025 promises to be an especially exciting edition, and why it's an event you won’t want to miss. He also spotlights two groundbreaking EU-funded research projects - Squeeze and AutoPiX - which are coordinated by our division and will be featured at the congress.
Watch the interviews here:
- Part 1: What to expect at EULAR 2025
- Part 2: EU projects SQUEEZE & AutoPiX – reshaping the future of rheumatology
In the second video, Daniel dives deeper into the innovative science behind these two ambitious projects and emphasizes how patient involvement is central to both initiatives. By actively engaging patients in the research process, we’re ensuring that their insights and experiences help shape the future of rheumatology care and innovation.
14.05.2025 - New Insights on Janus Kinase Inhibitors (JAKi) in Immune-Mediated Inflammatory Diseases
Two comprehensive Systematic Reviews Published in Annals of the Rheumatic Diseases
The treatment landscape of immune-mediated inflammatory diseases (IMIDs) has evolved significantly with the advent of Janus kinase inhibitors (JAKi). To provide a clearer and evidence-based perspective on the efficacy and safety of these agents, two extensive systematic literature reviews first-authored by Victoria Konzett, a junior rheumatologist from our division, have been published in the Annals of the Rheumatic Diseases (2025). These reviews formed the scientific backbone for the 2024 update of the international expert consensus statement on the use of JAK inhibitors in IMIDs.
17.03.2025 - Our department mourns the loss of Klaus Machold
It is with deep sadness that we bid farewell to Klaus Machold, an extraordinary person, an outstanding doctor, mentor, colleague and friend. His tireless commitment, his passion for rheumatology and his profound expertise have inspired and shaped several generations of doctors.
The MDR-RA Consortium in Milan, Italy, January 2025
29.01.2025 - Our Division is part of a European project on multi-drug resistant rheumatoid arthritis
The MDR-RA (Multi-Drug Resistance in Rheumatoid Arthritis) project has officially started: it’s an international research initiative, with a total budget of €8.4 million, funded by the European Union under the Horizon Europe program and the Swiss State Secretariat for Education, Research, and Innovation. The project, which is coordinated by Humanitas University, involves 23 partners from 12 European countries. In addition to MedUni Vienna, other renowned academic institutions, leading companies, healthcare organisations and patient associations are involved.
The AutoPiX-Konsortium in Vienna, December 2024
09.12.2024 - We are coordinating a new European IHI project to advance imaging in arthritis: AutoPiX!
Our division is coordinating AutoPiX, a new project involving European research partners, pharmaceutical companies, small and medium-sized enterprises (SMEs), and patient organisations, under the Innovative Health Initiative (IHI) public-private partnership to improve the diagnosis, treatment decisions, and monitoring of major rheumatic diseases. This newly launched IHI AutoPiX project will leverage AI to make clinical imaging more interpretable to scientists, clinicians, and patients.
To enhance imaging biomarkers for patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, the IHI-funded AutoPiX project brings together world-class pharmaceutical and medical technology partners with leading academic institutions.